Ticker: CRVS

Corvus Pharmaceuticals

Biotech Healthcare Biotechnology

Price 13.07

Reco Sell Potential 20 Risk 80 Updated 2026-07-27

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Company and Business Model

Corvus Pharmaceuticals is a healthcare company focused on developing immuno-oncology therapies for cancer treatment. Its core products include investigational drugs targeting specific cancer pathways, with a primary emphasis on enhancing the immune response against tumors. The company operates in the biotechnology segment, primarily generating revenue through research and development activities and potential future product sales.

Investment Profile

The investment profile of Corvus Pharmaceuticals is more aligned with growth investors, given its focus on developing innovative therapies in a high-risk sector. The lack of dividends and the company's current financial performance suggest a higher risk profile, making it less suitable for conservative investors. The stock may appeal to those with a longer investment horizon who are willing to accept volatility for potential future gains.

Category: Biotech Sector: Healthcare Industry: Biotechnology Investment style: Growth Horizon: Medium-term Company type: Small Cap

Fundamental metrics (experimental) Updated: 2026-07-25

EPS (TTM) — earnings per share for the last 12 months, $: -0.55
EPS surprise: -7.1%
20d volatility: 3.0%

AI recommendation changes

Date	Before	After	Reason
2026-07-07	Hold	Sell	Weak fundamentals and high risk limit upside potential.
2026-06-25	Sell	Hold	High volatility with uncertain fundamentals and mixed signals.
2026-06-03	Hold	Sell	scenario_deterioration
2026-06-01	Sell	Hold	Weak fundamentals and negative momentum signal high risk.
2026-05-16	Hold	Sell	scenario_deterioration
2026-05-08	—	Hold	Weak fundamentals and negative momentum signal high risk.
2026-05-08	Hold	Hold	Компания показывает значительную волатильность на рынке, особенно в краткосрочной перспективе, что увеличивает риск. Однако недавний рост на 78.36% за 120 дней может указывать на потенциал для дальнейшего роста.
2026-04-18	—	Hold	Компания показывает сильный рост за последние 120 дней, несмотря на недавнее снижение. Потенциал роста остается высоким, что делает её привлекательной для инвестиций.

Analyst forecasts

Date	Analyst	Action	Target	Price Then
2026-04-17	Goldman Sachs	Update	— → 40	15.04
2026-01-29	Mizuho Securities	Target Raised	20 → 30	20.54
2026-01-22	Jefferies	Target Raised	13 → 42	25.8
2026-01-21	Oppenheimer	Target Raised	15 → 32	22.537
2026-01-20	Barclays	Target Raised	16 → 28	21.41
2026-01-20	Mizuho Securities	Target Raised	13 → 20	19.5197
2026-01-20	H.C. Wainwright	Target Raised	11 → 27	18.22
2025-10-29	Mizuho Securities	Target Raised	11 → 13	7.553
2025-10-13	Barclays	Update	— → 16	6.93

News Page 1 of 1

Nothing yet